The Lancet, 398(10301), 665-674. Elsevier Limited Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6 LANCET r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname